PetMed Express Fiscal Q1 Results Beat Expectations

PetMed Express Fiscal Q1 Results Beat Expectations

Shares of PetMed Express were trading higher before Monday’s open after reporting better-than-expected fiscal Q1 profit and sales expectation. For Q1 ended June 30, the company reported a profit of $0.45 per share, up from $0.32 a year ago and above the Capital IQ consensus estimate of $0.38 per share. Total revenue increased to $79.7 million from $72.5 million a year ago, beating the estimated $77.3 million. Additionally, the company […]

Read More ˃
Mazor Robotics Sees Large Q2 Revenue Growth

Mazor Robotics Sees Large Q2 Revenue Growth

Israel-based medical device firm Mazor Robotics said Thursday that it expects to report record revenue of approximately $15.4 million for Q2, as compared to $8.3 million reported for the same period last year. Analysts polled by Capital IQ have been expecting Q2 sales of $12.1 million. During Q2, the company received purchase orders for 19 robotic systems, consisting of 16 Mazor X systems and three Renaissance systems.

Read More ˃
Dorian LPG Posts Fiscal Q4 EPS, Revenue Above Street

Dorian LPG Posts Fiscal Q4 EPS, Revenue Above Street

Dorian LPG reported Wednesday financial results for fiscal Q4, with earnings and revenue that both topped analysts’ expectations; it also provided guidance for fiscal 2017. For the quarter ended March 31, the owner and operator of LPG tankers posted adjusted earnings of $0.02 per share, compared with the prior-year period’s $0.60 per share. Analysts polled by Capital IQ were expecting a loss of $0.14 per share. Revenue was $47.6 million, […]

Read More ˃
Hamilton Lane Fiscal Q4 Earnings Beat Estimates

Hamilton Lane Fiscal Q4 Earnings Beat Estimates

Private markets asset management firm Hamilton Lane Inc. said Monday its fiscal Q4 adjusted earnings for the period ended March 31 amounted to $0.25 per share, beating analysts’ estimates as polled by Capital IQ by a penny and compared with no profit in the same period a year ago. The company also reported revenue of $46.7 million, in-line with estimates and beating $41.3 million in the same period a year […]

Read More ˃
bluebird bio Shares Jump

bluebird bio Shares Jump

Shares of bluebird bio shares touched their highest level since September 2015 on Tuesday after BMO Capital Markets upgraded the stock to outperform from market perform and raised its price target to $108 from $83 per share. BLUE was up 11% at $101.23 recently, trading in a new 52-week range between $36.62 and $101.75. The brokerage said it upgraded the biotechnology firm’s stock following the release of updated results on […]

Read More ˃